Skip to main content

Dermatology

EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU
Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC? Brief answer is no, but: -PsA > tortuous capillaries vs. PSO & HC -Abnormalities in PSO to be used as predictor of PsA? TBC... @RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
🚨EULAR PtC clinical & imaging features suspicious for progression to PsA Main take home messages ⬇️⬇️ Obesity, Nail Disease, Extensive PsO, Arthralgia, US detected synovio-entheseal involvement/abnormalities in US = risks factors of developing PsA in PsO pts. @Rheumnow #EULAR23
MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/xGPSA2oRis https://t.co/y7M42DlM7d
TNF Inhibitors and Acne? A literature review found 47 refractory acne pts Rx w/ TNFi; noting partial improvement (94%) or clearance (40%) & only 6% w/ adverse events. 17 pts had new-onset acne after Rx w/ TNFi for a different inflamm Dx. Odd! https://t.co/duHEIHBMyK https://t.co/br8NQZQE2r

Allergic Drug-Induced Arthritis (5.19.2023)

May 19, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.




  1. Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK

Read Article
RCT of 122 active plaque Psoriasis pts (38F, 55M) with low vitamin D (~15). Rx w/ either PBO or Vit D (100K IU, followed by 20K IU/wk x 4 mos). Vitamin D supplementation had no effect on psoriasis severity (but pts had mild PSO). https://t.co/JXtEBaop3c https://t.co/ScGtBUIrm0

Brepocitinib in Active Psoriatic Arthritis

May 17, 2023

Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.



Brepocitinib is an oral, selective Tyk2/JAK1 inhibitor with both

Read Article
JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/eVwQ6ITzD7 https://t.co/GZxVx77aV1

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

May 12, 2023

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients. The use of newer b/tsDMARD was hampered by limited

Read Article

One in Ten is Bad! (5.12.2023)

May 12, 2023

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Read Article
JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/OV4rRR6eCh https://t.co/uY9MnwGveV

National Population Insights (4.28.2023)

Apr 28, 2023

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article
JAMA Dermatology Patient Education page - Sarcoidosis of the Skin https://t.co/yDbwRUR8DK https://t.co/F8lsoh6s1l
JAMA Dermatology Patient Education page - Sarcoidosis of the Skin https://t.co/aPbTjl3pXv https://t.co/wCbjlUeFkj

Sex-Specific Differences in Psoriatic Arthritis

Apr 19, 2023

A systematic review of published literature on psoriatic arthritis (PsA), clinical features, disease activity, and patient-reported outcomes (PROs) shows generally higher levels of disease activity in women, compared to men with PsA.



A metanalysis of published reports on adults with

Read Article

Amgen Wins Otezla Patent Case - Brand Protected till 2028

Reuters
Apr 19, 2023

Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028.



The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey

Read Article
Atopic Disease Increases Osteoarthritis Risk Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis (OA). https://t.co/450DnhOfY5 https://t.co/zUfD4jhumY
RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https… https://t.co/OI5v1y5t0u
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

Atopic Disease Increases Osteoarthritis Risk

Mar 29, 2023

Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis.

Read Article
Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT
Dr. John Reveille on genetic sharing between AS, PsO, and IBD - multiple overlapping genetic signals @RheumNow #RNL2023 https://t.co/p3gvfTO732
NEJM Case: 44 yoF w/ 1wk hx of pustular rash, 1st on face, then legs. Also has ankle pain & odynophagia. PMHx oral ulcers. Exam: Aphthous ulcers & all labs were negative (ANA, ANCA, HIV, RPR, etc). Skin Bx= small-vessel vasculitis. What Dx? https://t.co/gxjXRaRKzq https://t.co/OYmC4om6hi
×